Human lung carcinomas express Fas ligand

Zitieren

Dateien zu dieser Ressource

Prüfsumme: MD5:5426d49c4b2cad375a589ec7e1382157

NIEHANS, Gloria A., Thomas BRUNNER, Sandra P. FRIZELLE, Jacob C. LISTON, Christopher T. SALERNO, Dennis J. KNAPP, Douglas R. GREEN, Robert A. KRATZKE, 1997. Human lung carcinomas express Fas ligand. In: Cancer Research. 57(6), pp. 1007-1012

@article{Niehans1997Human-14312, title={Human lung carcinomas express Fas ligand}, year={1997}, number={6}, volume={57}, journal={Cancer Research}, pages={1007--1012}, author={Niehans, Gloria A. and Brunner, Thomas and Frizelle, Sandra P. and Liston, Jacob C. and Salerno, Christopher T. and Knapp, Dennis J. and Green, Douglas R. and Kratzke, Robert A.} }

<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/rdf/resource/123456789/14312"> <dc:contributor>Salerno, Christopher T.</dc:contributor> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2011-07-29T09:06:42Z</dc:date> <dcterms:title>Human lung carcinomas express Fas ligand</dcterms:title> <dc:contributor>Green, Douglas R.</dc:contributor> <bibo:uri rdf:resource="http://kops.uni-konstanz.de/handle/123456789/14312"/> <dc:contributor>Knapp, Dennis J.</dc:contributor> <dcterms:bibliographicCitation>First publ. in: Cancer Research ; 57 (1997), 6. - pp. 1007-1012</dcterms:bibliographicCitation> <dc:rights>deposit-license</dc:rights> <dc:creator>Niehans, Gloria A.</dc:creator> <dc:creator>Frizelle, Sandra P.</dc:creator> <dcterms:abstract xml:lang="eng">To reach a clinically detectable size, neoplasms must be able to suppress or evade a host immune response. Activated T cells may enter apoptosis in the presence of Fas ligand (FasL) (1), and tissue expression of FasL has been shown to contribute to immune privilege in the eye and testis (2, 3). We have demonstrated that all human lung carcinoma cell lines tested (16 of 16) express a Mr 38,000 protein consistent with FasL by immunoblotting, whereas the majority of resected tumors (23 of 28) show positive staining for FasL by immunohistochemistry. DNA sequencing of reverse transcription-PCR products from lung cancer cells and resected lung tumors confirms the presence of human FasL mRNA in these neoplastic tissues. Furthermore, lung carcinoma cells are capable of killing a Fassensitive human T cell line (Jurkat) in coculture experiments; this killing was inhibited by a recombinant form of the soluble portion of the Fas receptor (FasFc). FasL expression by neoplastic cells represents a potential mechanism for peripheral deletion of tumor-reactive T-cell clones.</dcterms:abstract> <dc:creator>Knapp, Dennis J.</dc:creator> <dc:contributor>Brunner, Thomas</dc:contributor> <dc:creator>Green, Douglas R.</dc:creator> <dcterms:rights rdf:resource="http://nbn-resolving.org/urn:nbn:de:bsz:352-20140905103605204-4002607-1"/> <dc:creator>Brunner, Thomas</dc:creator> <dcterms:issued>1997</dcterms:issued> <dc:language>eng</dc:language> <dc:creator>Kratzke, Robert A.</dc:creator> <dc:contributor>Kratzke, Robert A.</dc:contributor> <dc:contributor>Niehans, Gloria A.</dc:contributor> <dc:creator>Liston, Jacob C.</dc:creator> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2011-07-29T09:06:42Z</dcterms:available> <dc:contributor>Liston, Jacob C.</dc:contributor> <dc:contributor>Frizelle, Sandra P.</dc:contributor> <dc:creator>Salerno, Christopher T.</dc:creator> </rdf:Description> </rdf:RDF>

Dateiabrufe seit 01.10.2014 (Informationen über die Zugriffsstatistik)

1997_Niehans_Human Lung Carci.pdf 158

Das Dokument erscheint in:

KOPS Suche


Stöbern

Mein Benutzerkonto